Investigation of tenascin-C, GDF-15 and pentraxin-3 levels in TYPE 2 diabetic patients with and without peripheral diabetic neuropathy

INVESTIGATION OF TENASCIN-C, GDF-15 AND PENTRAXIN-3 LEVELS IN TYPE 2 DIABETIC PATIENTS WITH AND WITHOUT PERIPHERAL DIABETIC NEUROPATHY Purpose: Diabetic peripheral neuropathy (DPN); It is one of the important chronic microvascular complications of diabetes. Many factors such as oxidative stress, endothelial dysfunction and triggered inflammation associated with hyperglycemia are thought to play a role in the pathophysiology of neuropathy. In this study, it was aimed to investigate the relationship between the plasma levels of Growth Differentiation Factor-15 (GDF-15), Pentraxin-3 (PTX-3) and Tenascin-C (TN-C) and neuropathy in patients with Type 2 diabetes. Materials and Methods: 56 patients with type 2 DM diagnosis and 30 healthy volunteers without systemic disease were included in the study. The patients were divided into 3 groups as Type 2 DM patients with and without peripheral distal symmetric polyneuropathy and the control group. Serum PTX-3, GDF-15, TN-C levels were measured and compared between the groups using the eliza method. Results: The mean TN-C serum level was 1.890±0.6 ng/ml, the highest in the neuropathy group, and the lowest in the control group, with 0.884±0.2 ng/ml. In the diabetic group without neuropathy, it was found to be 1.266±0.3 ng/ml lower than the group with neuropathy. This difference between the groups was found to be statistically significant (p:0.000). GDF-15 serum level was found to be 1.311±0.5ng/ml in the neuropathy group, 0.955±0.3 ng/ml in the non-neuropathy group, and 0.678±0.1 ng/ml in the control group, while it was found to be the lowest in the control group, while it was statistically significantly higher in the neuropathy patient group. found (p:0.000). At the same time, positive correlations were found between GDF-15 and TN-C and HbA1c. The mean PTX-3 level was 0.617±0.1 ng/ml in the neuropathy group, 0.780±0.2 ng/ml in the diabetic group without neuropathy, and 0.671±0.3 ng/ml in the control group. Serum PTX-3 level, which was found to be low in patients with DPN, was not statistically significant when compared with other groups (p:0.080). Conclusion: In our study, there was a significant relationship between increased GDF-15 and TN-C levels and DPN, but no significant relationship was found with PTX-3 levels. We think that GDF-15 and TN-C levels are biomarkers that will guide the screening, early diagnosis and treatment of DPN, but more comprehensive studies are needed in this area. Keywords: Diabetes Mellitus, Diabetic Peripheral Neuropathy, GDF-15, Pentraxin-3, Tenascin-C